Health 13 August 2026 Daily Monitor (Uganda)
Uganda Awaits New HIV Prevention Drug Doses Amidst High Demand
Uganda is expecting approximately 7,600 doses of Lenacapavir, a long-acting injectable HIV prevention drug, as current supplies dwindle due to high demand. The new drug offers a twice-yearly alternative to daily oral PrEP, with uptake increasing among both men and women. Source: https://www.monitor.co.ug/uganda/news/national/hiv-new-drug-gains-ground-as-uganda-awaits-about-7-600-doses-5556670
Lenacapavir, a novel injectable HIV prevention medication, is experiencing a surge in demand across Uganda, leading to stockouts at over 100 health facilities. The drug, marketed as YEZTUGO for PrEP, was approved last year and requires only two doses annually, providing nearly 100% protection against HIV infection in clinical trials.
The initial consignment of 19,200 doses received in February 2026 has been quickly depleted, highlighting a growing interest in this long-acting alternative to daily oral Pre-Exposure Prophylaxis (PrEP). While women still constitute the majority of recipients (around 56%), uptake among men is steadily increasing, particularly in older age groups.
Dr. Herbert Kadama, the Ministry of Health’s coordinator for PrEP, noted that the growing interest indicates a preference for less frequent dosing regimens. “People are very positive about taking it. So many people,” he stated.
Uganda is anticipating an additional 7,600 doses this month to meet the ongoing demand and facilitate new administrations. This influx is crucial as the nation continues its efforts to combat a significant HIV burden, with an estimated 1.5 million people living with HIV in the country.
Lenacapavir, a capsid inhibitor, works by interfering with the virus’s protective covering at various stages of its life cycle. Administered subcutaneously, it forms a reservoir that slowly releases the drug over six months. This method proves particularly beneficial for individuals who find daily medication challenging due to forgetfulness, stigma, or lifestyle factors.
Despite the positive reception and increasing availability, health officials emphasize that Lenacapavir protects only against HIV and not other sexually transmitted infections or unintended pregnancies. Comprehensive prevention strategies, including condom use and regular testing, remain essential. The drug is currently provided free of charge at selected public health facilities to individuals deemed at substantial risk of HIV infection.